Dataset from A Randomized Controlled Multicentered Phase 2/3 Study to Evaluate SHR-1210 (PD-1 Antibody) in Subjects With Advanced Hepatocellular Carcinoma (HCC) Who Failed or Intolerable to Prior Systemic Treatment
收藏NIAID Data Ecosystem2026-05-10 收录
下载链接：
https://doi.org/10.25934/PR00010077
下载链接
链接失效反馈官方服务：
资源简介：
This a randomized controlled Phase 2/3 study to evaluate the efficacy and safety of SHR-1210
in subjects with advanced HCC who failed or intolerable to prior systemic treatment. The
primary study hypothesis is that SHR-1210 treatment improves Objective Response Rate and
Overall Survival when compare with SOC.
创建时间：
2026-02-06
